Key Performance Indicators for Evaluation and Treatment of Early Alzheimer's Disease with Anti Amyloid Monoclonal Antibody in Neurology Community Clinics

Between April 2023 and December 2024, a total of 506 patients were enrolled in the program. Among them, 108 received treatment, 140 were pending treatment, and 258 were disqualified. Key metrics included: Negative AD Biomarker Rate: Percentage of patients with negative AD specific biomarker results as the reason for disqualification of treatment. Treatment Rate: Percentage of eligible patients receiving therapy, analyzed independently of insurance coverage. Door-to-Treatment Time: Time from first clinical evaluation to first infusion treatment. Dropout Rate: Proportion of patients discontinuing therapy. Rates of Amyloid Related Imaging Abnormalities (ARIA) CONCLUSIONS: The evaluation and treatment of early Alzheimer's disease with anti-amyloid monoclonal antibody therapy is both feasible and safe within community neurology clinics. Streamlined triaging, simplified care coordination, and rigorous quality and safety monitoring are critical for success. Monitoring key performance indicators-including 1) Negative AD Biomarker Rate, 2) Treatment Rate, 3) Door-to-Treatment time, 4) Dropout Rate, and 5) ARIA rates-facilitates the standardization and scalability of care delivery. These KPIs offer a structured approach to optimizing treatment outcomes and broadening access to disease-modifying therapies in real-world settings.